SRRT: A Protein Implicated in Disease and Cancer (G51593)

Target Name: SRRT

NCBI ID: G51593

SRRT

SRRT: A Protein Implicated in Disease and Cancer

SRRT (SRRTase) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of cysteine 鈥嬧?媝rotease (cysteine 鈥嬧?媝rotease) and is characterized by its ability to catalyze the chemical reaction known as arsonate hydration. This reaction involves the transfer of a phosphate group from a phosphate donor to a cysteine 鈥嬧?媟esidue on a target protein, resulting in the formation of a covalently bound phosphate salt.

SRRT is involved in a wide range of physiological processes in the body, including cell signaling, neurotransmission, and chromatin structure. It has been implicated in the development and progression of various diseases, including neurodegenerative disorders, diabetes, and cancer.

As a drug target, SRRT is a promising target for the development of new treatments for a variety of diseases. The ability of SRRT to catalyze the arsonate hydration reaction has led to the development of new compounds that can inhibit this reaction and prevent the formation of covalently bound phosphate salts. These compounds have been shown to be effective in preclinical studies for treating a range of diseases, including neurodegenerative disorders, diabetes, and cancer.

In addition to its potential as a drug target, SRRT is also a potential biomarker for a variety of diseases. The ability of SRRT to catalyze the arsonate hydration reaction is a key feature that can be used to diagnose and monitor the progression of certain diseases. For example, the levels of SRRT in the brain can be used to track the progression of neurodegenerative disorders, and the levels of SRRT in cancer cells can be used to monitor the effectiveness of anti-cancer treatments.

SRRT is a complex protein that is involved in a wide range of physiological processes in the body. Its ability to catalyze the arsonate hydration reaction has led to its implication in the development and progression of various diseases. As a drug target, SRRT is a promising target for the development of new treatments for a variety of diseases. In addition to its potential as a drug target, SRRT is also a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of SRRT in the biology of disease and its potential as a therapeutic target.

Protein Name: Serrate, RNA Effector Molecule

Functions: Acts as a mediator between the cap-binding complex (CBC) and the primary microRNAs (miRNAs) processing machinery during cell proliferation. Contributes to the stability and delivery of capped primary miRNA transcripts to the primary miRNA processing complex containing DGCR8 and DROSHA, thereby playing a role in RNA-mediated gene silencing (RNAi) by miRNAs. Binds capped RNAs (m7GpppG-capped RNA); however interaction is probably mediated via its interaction with NCBP1/CBP80 component of the CBC complex. Involved in cell cycle progression at S phase. Does not directly confer arsenite resistance but rather modulates arsenic sensitivity. Independently of its activity on miRNAs, necessary and sufficient to promote neural stem cell self-renewal. Does so by directly binding SOX2 promoter and positively regulating its transcription (By similarity)

The "SRRT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRRT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets